Evidence map›Paper›PMID 39296322›Full record

ArticleDialogues in health2024

An Indigenous-led buprenorphine-naloxone treatment program to address opioid use in remote Northern Canada.

Aleksandra M Zuk, Fatima Ahmed, Nadia A Charania, Celine Sutherland, Gisele Kataquapit, Robert J Moriarity, Nicholas D Spence, Leonard J S Tsuji, Eric N Liberda

Abstract read
In one paragraph

Article in Dialogues in health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aleksandra M ZukDepartment of Physical and Environmental Sciences, University of Toronto, Toronto, Ontario, Canada.
Fatima AhmedSchool of Occupational and Public Health, Toronto Metropolitan University, Toronto, Ontario, Canada.
Nadia A CharaniaDepartment of Public Health, Auckland University of Technology, Auckland, New Zealand.
Celine SutherlandFort Albany First Nation, Fort Albany, Ontario, Canada.
Gisele KataquapitPeetabeck Health Services, Fort Albany First Nation, Fort Albany, Ontario, Canada.
Robert J MoriaritySchool of Occupational and Public Health, Toronto Metropolitan University, Toronto, Ontario, Canada.
Nicholas D SpenceDepartment of Physical and Environmental Sciences, University of Toronto, Toronto, Ontario, Canada.
Leonard J S TsujiDepartment of Physical and Environmental Sciences, University of Toronto, Toronto, Ontario, Canada.
Eric N LiberdaSchool of Occupational and Public Health, Toronto Metropolitan University, Toronto, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/purpose: In response to the opioid use challenges exacerbated from the COVID-19 pandemic, Fort Albany First Nation (FAFN), a remote Cree First Nation community situated in subarctic Ontario, Canada, implemented a buprenorphine-naloxone program. The newly initiated program was collaboratively developed by First Nations' nurses and community leaders, driven by the community's strengths, resilience, and forward-thinking approach. Using the First Nations Information Governance Centre strengths-based model, this article examines discussions with four community leaders to identify key strengths and challenges that emerged during the implementation of this program. Methods: this qualitative study amplify the positive aspects and community strengths through the power of oral narratives. We conducted 20 semi-structured face-to-face interviews with community members who helped lead FAFN's COVID-19 pandemic response. Utilizing the Medicine Wheel framework, this work introduces a holistic model for the buprenorphine-naloxone program that addresses the cognitive, physical, spiritual, and emotional dimensions of well-being. Results: Recommendations to support this initiative included the need for culturally competent staff, customized education programs, and the expanding of the program. Additionally, there is a pressing need for increased funding to support these initiatives effectively and sustainably. The development of this program, despite challenges, underscores the vital role of community leadership and cultural sensitivity to address the opioid crisis in a positive and culturally safe manner. Conclusion: The study highlights the successes of the buprenorphine-naloxone program, which was developed in response to the needs arising from the pandemic, specifically addressing community members suffering from opioid addiction. The timely funding for this program came as the urgent needs of community members became apparent due to pandemic lockdowns and isolation. Holistic care, including mental health services and fostering community relations, is important. By centering conversations on community strengths and advocating for culturally sensitive mental health strategies that nurture well-being, resilience, and empowerment, these findings can be adapted and expanded to support other Indigenous communities contending with opioid addiction.

Indexed as

Buprenorphine-naloxoneCommunity-based treatmentIndigenous healthOpioid use disorderStrength-basedWellbeing

Identifiers

PMID39296322
PMCPMC11408382

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.